ウィルムス腫瘍治療市場- 世界の産業規模、シェア、動向、機会、予測、種類別、治療別、エンドユーザー別、地域別、競合別、2020～2030年

ウィルムス腫瘍治療の世界市場規模は、2024年に15億5,000万米ドルとなり、2030年までの年間平均成長率（CAGR）は4.60％と、予測期間中に着実な成長が見込まれています。

この市場は、より大きながん領域の医薬品・ヘルスケア分野の中でも重要なセグメントです。ウィルムス腫瘍は腎芽細胞腫としても知られ、主に3～4歳の小児が罹患するまれな小児腎臓がんです。ウィルムス腫瘍治療市場には、手術、化学療法、放射線療法、場合によっては標的療法や免疫療法など、さまざまな治療アプローチが含まれます。

市場成長を促す主な要因の一つは、ウィルムス腫瘍の世界の発生率の上昇です。ウィルムス腫瘍は希少がんとして分類されているにもかかわらず、小児における腎臓がんの中で最も罹患率の高いもの1つです。早期診断と医療画像技術の進歩により発見率が向上し、効果的な治療に対する需要がさらに高まっています。手術、特に腎摘除術（罹患した腎臓を摘出すること）は、依然として治療の要です。しかし、化学療法や場合によっては放射線療法は、再発を予防し生存率を向上させるために不可欠です。

製薬部門は、小児患者のニーズに合わせた新しい化学療法剤や革新的な治療法の開発において重要な役割を果たしています。さらに、現在進行中の調査では、標的療法や免疫療法が検討されており、健康な組織へのダメージを最小限に抑えながら腫瘍増殖の根底にある遺伝的・分子的因子を標的とすることで、治療状況を一変させ、患者により良い結果をもたらす可能性があります。

世界の競合情勢としては、数多くの製薬会社、研究機関、ヘルスケアプロバイダーが臨床試験や医薬品開発に従事していることが挙げられます。さらに、学術界、産業界、規制当局間のパートナーシップがイノベーションを促進し、新たな治療法の承認を促進しています。

主な市場促進要因

ウィルムス腫瘍の発生率の増加

主な市場課題

認知度の低下と早期診断

主要市場動向

個別化医療と標的治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 ウィルムス腫瘍治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 市場マップ

第5章 アジア太平洋地域のウィルムス腫瘍治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別
  • 治療別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のウィルムス腫瘍治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のウィルムス腫瘍治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のウィルムス腫瘍治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのウィルムス腫瘍治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のウィルムス腫瘍治療： SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Cepham Life Sciences
• Pfizer Inc.
• Getwell Pharmaceuticals
• Amneal Pharmaceuticals LLC
• Medline Industries, LP.
• Sandoz International GmbH
• Teva Pharmaceuticals Limited
• Accord Healthcare Ireland Ltd.
• Eugia US LLC
• Fresenius Kabi AG

第15章 戦略的提言

第16章 調査会社について・免責事項

The global Wilms Tumor Treatment Market was valued at USD 1.55 billion in 2024 and is expected to experience steady growth during the forecast period, with a compound annual growth rate (CAGR) of 4.60% through 2030. This market is a critical segment within the larger oncology pharmaceutical and healthcare sectors. Wilms tumor, also known as nephroblastoma, is a rare form of pediatric kidney cancer that predominantly affects children between the ages of 3 and 4. The treatment market for Wilms tumor includes various therapeutic approaches such as surgery, chemotherapy, radiation therapy, and, in some cases, targeted therapies or immunotherapies.

One of the primary factors driving market growth is the rising incidence of Wilms tumor worldwide. Despite being classified as rare, it remains one of the most prevalent types of kidney cancer in children. Advances in early diagnosis and medical imaging technologies have improved detection rates, further increasing the demand for effective treatments. Surgery, particularly nephrectomy (the removal of the affected kidney), continues to be the cornerstone of treatment. However, chemotherapy and, in certain cases, radiation therapy, are critical for preventing relapse and improving survival rates.

The pharmaceutical sector plays a key role in developing new chemotherapeutic agents and innovative treatment options tailored to the needs of pediatric patients. Furthermore, ongoing research efforts are exploring targeted therapies and immunotherapies, which could transform the treatment landscape by targeting the genetic and molecular factors underlying tumor growth while minimizing damage to healthy tissue, thus offering better outcomes for patients.

The global market for Wilms tumor treatment is marked by a competitive landscape, with numerous pharmaceutical companies, research institutions, and healthcare providers engaged in clinical trials and drug development. Additionally, partnerships between academia, industry, and regulatory bodies are fostering innovation and facilitating the approval of new treatments.

Key Market Drivers

Increasing Incidence of Wilms Tumor

The growing number of Wilms tumor cases is a major factor driving the expansion of the market. Annually, approximately 400,000 children and adolescents (ages 0-19) are diagnosed with cancer, with leukemia, brain tumors, lymphomas, neuroblastoma, and Wilms tumor among the most common types. In high-income countries, where advanced medical infrastructure and specialized oncology services are widely available, over 80% of pediatric cancer cases are successfully treated. However, in low- and middle-income countries (LMICs), where access to state-of-the-art therapies and specialized care is limited, the survival rate drops to below 30%. This stark contrast highlights the critical need for increased healthcare investments, strategic partnerships, and innovative treatment delivery models to address disparities in pediatric oncology outcomes globally. As the number of diagnosed cases continues to rise, so too does the demand for effective treatment solutions, prompting more investment in research, drug development, and healthcare infrastructure.

Key Market Challenges

Limited Awareness and Early Diagnosis

A significant challenge facing the global Wilms tumor treatment market is the lack of awareness and delayed diagnosis. The rarity of Wilms tumor and its resemblance to more common childhood ailments often leads to missed or delayed diagnoses, which can result in more advanced disease stages and poorer outcomes. Healthcare providers may not immediately consider Wilms tumor when children present with symptoms like abdominal pain or swelling, leading to potential misdiagnoses or delayed referrals to specialists. This delay can result in the progression of the cancer, necessitating more aggressive treatments and reducing the likelihood of a complete cure. Furthermore, parents and caregivers may not recognize the signs of Wilms tumor, with symptoms often being mistaken for less severe conditions. This lack of awareness contributes to delayed diagnoses and subsequent treatment initiation.

Key Market Trends

Personalized Medicine and Targeted Therapies

Personalized medicine and targeted therapies are rapidly transforming the Wilms tumor treatment landscape. Historically, treatment for Wilms tumor followed a one-size-fits-all approach. However, advancements in genetic profiling and molecular diagnostics are enabling more precise, individualized treatment strategies. By identifying the specific genetic abnormalities driving tumor growth, healthcare providers can select targeted therapies that specifically address these issues, improving treatment effectiveness and minimizing harm to healthy tissue. This precision medicine approach is revolutionizing how Wilms tumor is managed, offering new hope for improved patient outcomes.

Key Market Players

• Cepham Life Sciences
• Pfizer Inc.
• Getwell Pharmaceuticals
• Amneal Pharmaceuticals LLC
• Medline Industries, LP
• Sandoz International GmbH
• Teva Pharmaceuticals Limited
• Accord Healthcare Ireland Ltd.
• Eugia US LLC
• Fresenius Kabi AG

Market Segmentation: The global Wilms Tumor Treatment Market is segmented as follows:

• By Type
• Favorable Histology
• Anaplastic Histology
• By Treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Other Therapies
• By End-User
• Hospitals
• Cancer Research Centers
• Academic and Research Institutions
• Other Facilities
• By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

The market features a competitive environment, with a diverse range of key players involved in clinical trials and drug development. Additionally, collaborations between academic institutions, the pharmaceutical industry, and regulatory bodies are driving innovation and enabling the approval of new treatments.

Available Customizations

This report on the Global Wilms Tumor Treatment Market offers customization options tailored to specific business needs.

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Wilms Tumor Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Favorable Histology, Anaplastic Histology)
  • 4.2.2. By Treatment (Surgery, Chemotherapy, Radiation Therapy, Others)
  • 4.2.3. By End User (Hospitals, Cancer Research Centers, Academic and Research Institutes, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatment
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Wilms Tumor Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Wilms Tumor Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By End User
  • 5.3.2. India Wilms Tumor Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Wilms Tumor Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Wilms Tumor Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Wilms Tumor Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By End User

6. Europe Wilms Tumor Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Wilms Tumor Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Wilms Tumor Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Wilms Tumor Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Wilms Tumor Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Wilms Tumor Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By End User

7. North America Wilms Tumor Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Wilms Tumor Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Wilms Tumor Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Wilms Tumor Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User

8. South America Wilms Tumor Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Wilms Tumor Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Wilms Tumor Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Wilms Tumor Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User

9. Middle East and Africa Wilms Tumor Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Wilms Tumor Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Wilms Tumor Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Wilms Tumor Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Wilms Tumor Treatment: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Cepham Life Sciences
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Getwell Pharmaceuticals
• 14.4. Amneal Pharmaceuticals LLC
• 14.5. Medline Industries, LP.
• 14.6. Sandoz International GmbH
• 14.7. Teva Pharmaceuticals Limited
• 14.8. Accord Healthcare Ireland Ltd.
• 14.9. Eugia US LLC
• 14.10. Fresenius Kabi AG

15. Strategic Recommendations

16. About Us & Disclaimer